FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2052606181> ?p ?o ?g. }

• W2052606181 endingPage "571" @default.
• W2052606181 startingPage "565" @default.
• W2052606181 abstract "AllergyVolume 39, Issue 8 p. 565-571 Ciclosporin (Cyclosporin A): Prototype of a New Generation of Immunosuppressive Drugs K. Bendtzen, Corresponding Author K. Bendtzen Medical Department TA, The State University Hospital, Copenhagen, DenmarkAddress: Klaus Bendtzen, Medical Department TA, University Hospital of Copenhagen, Tagensvej 20, DK-2200 Copenhagen N, DenmarkSearch for more papers by this author K. Bendtzen, Corresponding Author K. Bendtzen Medical Department TA, The State University Hospital, Copenhagen, DenmarkAddress: Klaus Bendtzen, Medical Department TA, University Hospital of Copenhagen, Tagensvej 20, DK-2200 Copenhagen N, DenmarkSearch for more papers by this author First published: November 1984 https://doi.org/10.1111/j.1398-9995.1984.tb01976.xCitations: 12AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Attallah, A. M., Urritia-Shaw, A., Yeatman, T. J. & Folks, T.: Effect of the new immunosuppressive agent cyclosporin-A on natural killer cell and antibody-dependent cell-mediated cytotoxic activity. Int. Arch. Allergy Appl. Immunol. 65, 465–469, 1981. 2 Baldwin, W. M., Hutchinson, I. F., Meijer, C. J. L. M. & Tilney, N. L.: Immune responses to organ allografts. III. 18. Marked decrease in medullary thymocytes and splenic T lymphocytes after cyclosporin A treatment. Transplantation 31, 117–120, 1981. 3 Bendtzen, K.: Induction of antigen-specific lymphocyte unresponsiveness in vitro: Possible role of divalent cations and defective function of human T-cell-activating factor (TAF). Cell. Immunol. 66, 152–163, 1982. 4 Bendtzen, K.: Biological properties of interleukins. Allergy 38, 219–226, 1983. 5 Bendtzen, K. & Dinarello, C. A.: Mechanism of action of cyclosporin A. Effect on T-cell-binding of interleukin 1 and antagonizing effect of insulin. Scand. J. Immunol. 20, 43–51, 1984. 6 Bendtzen, K. & Petersen, J.: Effects of cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. I. T-cell-activating factor (IL-1) abrogates CyA- but not MP-induced suppression of antigen-induced lymphokine production. Immunol. Lett. 5, 79–83, 1982. 7 Bendtzen, K. & Petersen, J.: Effect of cyclosporin A (CyA) on the immune response. CyA competitively inhibits the function of monocyte/macrophage-derived T lymphocyte-activating factor(s). Immunol. Lett. 5, 331–336, 1982. 8 Bendtzen, K., Petersen, J. & Soeberg, B.: Effects of 24. cyclosporin A (CyA) and methylprednisolone (MP) on the immune response. II. Further studies of the monocyte - T cell interactions leading to iymphokine production. Acta Pathol. Microbiol. Immunol. Scand. [C] 91, 159–168, 1983. 9 Bendtzen, K. & Thomsen, M.: The T cell suppressive function of cyclosporin A is counteracted by insulin. IRCS Med. Sci. 12, 280–281, 1984. 10 Bendtzen, K., Tvede, N., Andersen, V. & Bendixen, G.: Cyclosporin for polymyositis. Lancet 1, 792–793, 1984. 11 Bird, A. G., McLachlan, S. M. & Britton, S.: Cyclosporin A promotes spontaneous outgrowth in vitro of Epstein- Barr virus-induced B-cell lines. Nature 289, 300–301, 1981. 12 Borel, J. F.: The history of cyclosporin A and its significance. In D. J. G. White, (ed.): Cyclosporin A, pp. 5–17, Elsevier Biomedical Press, Amsterdam , 1982. 13 Borel, J. F., Feurer, C., Gubler, H. U. & Stähelin, H.: Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 6/4, 468–475, 1976. 14 Borel, J. F., Feurer, C., Magnee, C. & Stähelin, H.: Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology 32, 1017–1027, 1977. 15 Britton, S. & Palacios, R.: Cyclosporin A - Usefulness risks and mechanism of action. Immunol. Rev. 65, 5–22, 1982. 16 Bunjes, D., Hardt, C., Röllinghoff, M. & Wagner, H.: Cyclosporin A mediates immunosuppression of primary cytotoxic T cell responses by impairing the release of interleukin 1 and interleukin 2. Eur. J. Immunol. 11, 657–661, 1981. 17 Calne, R. Y., White, D. J. G., Thiru, S., et al.: Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 2, 1323–1327, 1978. 18 Canadian Multicentre Transplant Study Group: A randomized clinical trial of cyclosporine in cadaveric renal transplantation. N. Engl. J. Med. 309, 809–815, 1983. 19 European Multicentre Trial Group: Cyclosporin in cadaveric renal transplantation: One-year follow-up of a multicentre trial. Lancet 2, 986–989, 1983. 20 Graf, U., Marbet, U., Müller, W. & Thiel, G.: Cyclosporin A – Wirkungen und nebenwirkungen bei der behandlung der chronischen polyarthritis und der psoriasisarthritis. Immunol. Infekt. 9, 20–28, 1981. 21 Helderman, J. H., Reynolds, T. C. & Strom, T. B.: The insulin receptor as a universal marker of activated lymphocytes. Eur. J. Immunol. 8, 589–595, 1978. 22 Hess, A. D. & Tutschka, P. J.: Effect of cyclosporin A on human lymphocyte responses in vitro. I. CsA allows for the expression of alloantigen-activated suppressor cells while preferentially inhibiting the induction of cytolytic effector lymphocytes in MLR. J. Immunol. 124, 2601–2608, 1980. 23 Hess, A. D., Tutschka, P. J., Pu, Z. & Santos, G. W.: Effect of cyclosporin A on human lymphocyte responses in vitro. IV. Production of T cell stimulatory growth factors and development of responsiveness to these growth factors in CsA-treated primary MLR cultures. J. J. Immunol. 128, 360–367, 1982. 24 Hess, A. D., Tutschka, P. J. & Santos, G. W.: Effect of cyclosporin A on human lymphocyte responses in vitro. II. Induction of specific alloantigen unresponsiveness mediated by a nylon wool adherent suppressor cell. J. Immunol. 126, 961–968, 1981. 25 Hutchinson, I. F., Shadur, C. A., Duarte, J. S. A., Strom, T. B. & Tilney, N. L.: Cyclosporin A spares selectively lymphocytes with donor-specific suppressor characteristics. Transplantation 32, 210–216, 1981. 26 Isenberg, D. A., Snaith, M. L., Morrow, W. J. W., el al.: Cyclosporin A for the treatment of systemic lupus erythematosus. Int. J. Immunopharmacol. 3, 163–165, 1981. 27 Jamieson, S. W., Reitz, B. A., Oyer, P. E., et al.: Combined heart and lung transplantation. Lancet 1, 1130–1132, 1983. 28 Kharazmi, A., Svenson, M., Nielsen, H. & Birgens, H. S.: Effect of cyclosporin A on human neutrophil and monocyte function. Immunology (submitted). 29 Kostakis, A. J., White, D. J. G. & Calne, R. Y.: Prolongation of rat heart allograft survival by cyclosporin A. IRCS Med. Sci. 5, 280, 1977. 30 Larsson, E. L.: Cyclosporin A and dexamethasone suppress T cell responses by selectively acting at distinct sites of the triggering process. J. Immunol. 124, 2828–2833, 1980. 31 Laupacis, A., Stiller, C. R., Gardell, C., et al.: Cyclosporin prevents diabetes in BB Wistar rats. Lancet 1, 10–11, 1983. 32 LeGrue, S. J., Friedman, A. W. & Kahan, B. D.: Binding of cyclosporine by human lymphocytes and phospholipid vesicles. J. Immunol. 131, 712–718, 1983. 33 Mann, D. L., Mendell, N., Kahn, C. R. & Johnson, A. H.: In vitro lymphocyte proliferation response to therapeutic insulin components. J. Clin. Invest. 72, 1130–1138, 1983. 34 Müller-Hermelink, H. K., Kaiserling, E. & Sonntag, H. G.: Modulation of epithelioid cell granuloma formation to apathogenic mycobacteria by cyclosporin A. Pathol. Res. Pract. 175, 80–96, 1982. 35 Muraguchi, A., Butler, J. L., Kehrl, J. H., Falkoff, R. J. M. & Fauci, A. S.: Selective suppression of an early step in human B cell activation by cyclosporin A. J. Exp. Med. 158, 690–702, 1983. 36 Nickell, S. P., Scheibel, L. W. & Cole, G. A.: Inhibition by cyclosporin A of rodent malaria in vivo and human malaria in vitro. Inf. Immunity 37, 1093–1100, 1982. 37 Nussenblatt, R. B., Rook, A. H., Wacker, W. B., Palestine, A. G., Scher, I. & Gery, I.: Treatment of intraocular inflammatory disease with cyclosporin A. Lancet 2, 235–238, 1983. 38 Palacios, R. & Möller, G.: Cyclosporin A blocks receptors for HLA-DR antigens on T cells. Nature 290, 792–794, 1981. 39 Pedersen, C., Permin, H., Skov, P. S., et al.: Inhibitory effect of cyclosporin A on histamine release from human leukocytes and rat mast cells. Allergy (In press). 40 Powles, R. L., Barrett, A. J., Clink, H. M., Kay, H. E. M., Sloane, J. & McElwain, T. J.: Cyclosporin A for the treatment of graft-versus-host disease in man. Lancet 2, 1327–1331, 1978. 41 Puttick, L., Pollock, A. & Fairburn, E.: Treatment of Sezary syndrome with cyclosporin A. J. R. Soc. Med. 76, 1063–1065, 1983. 42 Rebuck, A. S., Stiller, C. R., Braude, A. C., Laupacis, A., Cohen, R. D. & Chapman, K. R.: Cyclosporin for pulmonary sarcoidosis. Lancet 1, 1174, 1984. 43 Ryffel, B., Götz, U. & Heuberger, B.: Cyclosporin receptors on human lymphocytes. J. Immunol. 129, 1978–1982, 1982. 44 Schlossman, S. F., Meuer, S. C., Acuto, O., Morimoto, C. & Reinherz, E. L.: Human T lymphocytes: Their differentiative history and functional program. Progr. Immunol. 5, 1069–1078, 1983. 45 Starzl, T. E., Klintmalm, G. B. G., Porter, K. A., Iwatsuki, S. & Schröter, G. P. J.: Liver transplantation with use of cyclosporin A and prednisone. N. Engl. J. Med. 305, 266–269, 1981. 46 Starzl, T. E., Porter, K. A., Iwatsuki, S., et al.: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1, 583–587, 1984. 47 Stiller, C. R., Dupre, J., Gent, M., et al.: Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 223, 1362–1367, 1984. 48 Stryckmans, P. A., Dumont, J. P., Velu, T. & Debus-scher, L.: Cyclosporine in refractory severe a plastic anemia. N. Engl. J. Med. 310, 655–656, 1984. 49 Thomas, H. C., Routhier, G., Epstein, O., Goldstein, G., Janossy, G. & Sherlock, S.: Cyclosporin A in primary biliary cirrhosis. Gastroenterology 79, 1059, 1980. 50 Thomson, A. W.: Immunobiology of cyclosporin A. Aust. J. Exp. Biol. Med. Sci. 61, 147–172, 1983. 51 Tosato, G., Pike, S. E., Koski, I. R. & Blaese, R. M.: Selective inhibition of immunoregulatory cell functions by cyclosporin A. J. Immunol. 128, 1986–1991, 1982. 52 Wenger, R.: Chemistry of cyclosporin. In D. J. G. White, (ed.): Cyclosporin A, pp. 19–34, Elsevier Biomedical Press, Amsterdam , 1982. 53 White, D. J. G.: Cyclosporin A. Clinical pharmacology and therapeutic potential. Drugs 24, 322–334, 1982. 54 White, D. J. G. & Calne, R. Y.: The use of cyclosporin A immunosuppression in organ grafting. Immunol. Rev. 65, 115–131, 1982. 55 Zabel, P., Leimenstoll, G. & Gross, W. L.: Cyclosporin for acute dertnatomyositis. Lancet 1, 343-, 1984. Citing Literature Volume39, Issue8November 1984Pages 565-571 ReferencesRelatedInformation" @default.
• W2052606181 created "2016-06-24" @default.
• W2052606181 creator A5053483999 @default.
• W2052606181 date "1984-11-01" @default.
• W2052606181 modified "2023-09-24" @default.
• W2052606181 title "Ciclosporin (Cyclosporin A): Prototype of a New Generation of Immunosuppressive Drugs" @default.
• W2052606181 cites W1498779417 @default.
• W2052606181 cites W1523681315 @default.
• W2052606181 cites W1552551430 @default.
• W2052606181 cites W1607142135 @default.
• W2052606181 cites W1758635778 @default.
• W2052606181 cites W1824282157 @default.
• W2052606181 cites W1858820748 @default.
• W2052606181 cites W1956619778 @default.
• W2052606181 cites W1968951087 @default.
• W2052606181 cites W1986742496 @default.
• W2052606181 cites W1991972231 @default.
• W2052606181 cites W1992517973 @default.
• W2052606181 cites W1994928270 @default.
• W2052606181 cites W1997411530 @default.
• W2052606181 cites W2005064077 @default.
• W2052606181 cites W2013391726 @default.
• W2052606181 cites W2023406953 @default.
• W2052606181 cites W2025451399 @default.
• W2052606181 cites W2029805256 @default.
• W2052606181 cites W2034683890 @default.
• W2052606181 cites W2047376004 @default.
• W2052606181 cites W2047751652 @default.
• W2052606181 cites W2055504983 @default.
• W2052606181 cites W2059409746 @default.
• W2052606181 cites W2069962332 @default.
• W2052606181 cites W2070447912 @default.
• W2052606181 cites W2075015540 @default.
• W2052606181 cites W2076346106 @default.
• W2052606181 cites W2076595756 @default.
• W2052606181 cites W2079125682 @default.
• W2052606181 cites W2080064179 @default.
• W2052606181 cites W2083998637 @default.
• W2052606181 cites W2093507929 @default.
• W2052606181 cites W2093662571 @default.
• W2052606181 cites W2097843691 @default.
• W2052606181 cites W2111243602 @default.
• W2052606181 cites W2137858837 @default.
• W2052606181 cites W2139597486 @default.
• W2052606181 cites W2164320765 @default.
• W2052606181 cites W2418153793 @default.
• W2052606181 cites W4244697632 @default.
• W2052606181 cites W4253710446 @default.
• W2052606181 doi "https://doi.org/10.1111/j.1398-9995.1984.tb01976.x" @default.
• W2052606181 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/6397073" @default.
• W2052606181 hasPublicationYear "1984" @default.
• W2052606181 type Work @default.
• W2052606181 sameAs 2052606181 @default.
• W2052606181 citedByCount "13" @default.
• W2052606181 countsByYear W20526061812015 @default.
• W2052606181 crossrefType "journal-article" @default.
• W2052606181 hasAuthorship W2052606181A5053483999 @default.
• W2052606181 hasConcept C126322002 @default.
• W2052606181 hasConcept C203014093 @default.
• W2052606181 hasConcept C2776535732 @default.
• W2052606181 hasConcept C2776694085 @default.
• W2052606181 hasConcept C2779528694 @default.
• W2052606181 hasConcept C2911091166 @default.
• W2052606181 hasConcept C71924100 @default.
• W2052606181 hasConcept C98274493 @default.
• W2052606181 hasConceptScore W2052606181C126322002 @default.
• W2052606181 hasConceptScore W2052606181C203014093 @default.
• W2052606181 hasConceptScore W2052606181C2776535732 @default.
• W2052606181 hasConceptScore W2052606181C2776694085 @default.
• W2052606181 hasConceptScore W2052606181C2779528694 @default.
• W2052606181 hasConceptScore W2052606181C2911091166 @default.
• W2052606181 hasConceptScore W2052606181C71924100 @default.
• W2052606181 hasConceptScore W2052606181C98274493 @default.
• W2052606181 hasIssue "8" @default.
• W2052606181 hasLocation W20526061811 @default.
• W2052606181 hasLocation W20526061812 @default.
• W2052606181 hasOpenAccess W2052606181 @default.
• W2052606181 hasPrimaryLocation W20526061811 @default.
• W2052606181 hasRelatedWork W2011373848 @default.
• W2052606181 hasRelatedWork W2041172286 @default.
• W2052606181 hasRelatedWork W2052606181 @default.
• W2052606181 hasRelatedWork W2056661731 @default.
• W2052606181 hasRelatedWork W2058219920 @default.
• W2052606181 hasRelatedWork W2059117179 @default.
• W2052606181 hasRelatedWork W2083039487 @default.
• W2052606181 hasRelatedWork W2091216349 @default.
• W2052606181 hasRelatedWork W2099099000 @default.
• W2052606181 hasRelatedWork W4211072483 @default.
• W2052606181 hasVolume "39" @default.
• W2052606181 isParatext "false" @default.
• W2052606181 isRetracted "false" @default.
• W2052606181 magId "2052606181" @default.
• W2052606181 workType "article" @default.